Expression of urine miR-26a and miR-146a in patients with lupus nephritis and predictive value for disease activity
Objective To analyze the expression of urine miR-26a and miR-146a in patients with lupus nephritis(LN)and predictive value for disease activity.Methods A total of 158 LN patients who were hospitalized in our hospital from January 2021 to December 2022 were selected and divided into LN stable group(88 cases)and LN active group(70 cases)according to systemic lupus erythematosis disease activity index(SLEDAI),60 cases healthy people who underwent physical examination in our hospital during the same period were selected as the control group.The general data and routine laboratory indexes of the three groups were compared.Multivariate Logistic regression analysis was used to analyze the factors affecting the activity of LN.The efficacy of urine miR-26a and miR-146a in predicting disease activity in LN patients was analyzed.Results The levels of complement C3,complement C4,hemoglobin,albumin,and the expressions of urine miR-26a and miR-146a in the LN active group and the LN stable group were lower than those in the control group,the differences were statistically significant(P<0.05).The levels of complement C4,hemoglobin,albumin,and the expressions of urine miR-26a and miR-146a in the LN active group were lower than those in the LN stable group,and the uric acid level was higher than that in the LN stable group(P<0.05).Multivariate Logistic regression analysis showed that urine miR-26a and miR-146a were the factors affecting the disease activity of LN patients(P<0.05).The receiver operating characteristic(AUC)of urine miR-26a,miR-146a and the combination of the two in predicting the disease activity of LN patients were 0.773,0.686 and 0.876,respectively.The combined predictive value was better than that of urine miR-26a and miR-146a alone predictive(P=0.037,0.000).Conclusion The expression of miR-26a and miR-146a in the urine of LN patients is decreased,and the combination of the two is more valuable in predicting the disease activity of LN.